A message from Chris Chen, CEO
A message from Chris Chen, CEO
Update Related to the Coronavirus Outbreak
Neutralizing Antibodies for Novel Coronavirus
WuXi Biologics is a leading global open-access technology platform company offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. Across the global biologics research and development community, we enable our partners to find innovative biological treatments for diseases worldwide.
With our one-stop service offering, project management team, industry leading scale-out manufacturing paradigm, and robust global supply chain, WuXi Biologics eliminates the time-consuming project hand-offs and troubleshooting that come with the conventional multi-vendor drug development model.
Capacities & Capabilities
Our distinctive technical capabilities and open-access technology platform allow our customers to initiate a project at any stage in the discovery and development process. We provide 6 discovery platforms for lead identification and have assembled one of the largest development teams in the global biologics industry, with more than 2,500 scientists and engineers. We also operate one of the world’s largest cell-culture development laboratories, with more than 260 bioreactors, each with individual capacity ranging from 1 L to 200 L. And we operate multiple clinical and commercial drug-substance and drug-product manufacturing facilities, including the world’s largest disposable bioreactor-based biologics commercial-manufacturing facility. Our current GMP manufacturing capacity is 40,000 L and growing to 280,000 L across five countries by 2022.
We provide 6 technology platforms and a fully integrated discovery engine that includes custom protein generation, as well as antibody-developability and -manufacturability assessment.
With one of the world’s largest biologics development teams, we cover all aspects of your product development including cell line engineering, assay, and formulation, as well as upstream and downstream process development.
We maintain Asia’s first non-state-run biosafety lab for viral clearance, CLC, and UPB testing. Protein characterization, release, and stability testing are also available in-house.
We utilize disposable bioreactors for fed-batch and perfusion manufacturing (50 L to 2,000 L) in multiple facilities (in Wuxi and Shanghai).
We have built the world’s largest disposable bioreactor-based biologics commercial manufacturing facility, with a total manufacturing capacity of 30,000 L.
We run multiple drug product / parenteral formulation, fill & finish facilities (producing up to 12,000 vials per hour or 100,000 vials per batch). These are available for both liquid and lyo fills.
Experience & Expertise
WuXi Biologics’ leadership team consists of industry experts each with more than 20 years of experience in biological drug development in the U.S., EU and China. At WuXi Biologics, this team has contributed to 1 BLA and 100 worldwide INDs.
WuXi Biologics has more than 450 scientists from large pharma and small biotech organizations around the world, covering all facets of drug development from discovery to the manufacturing of final drug products.
WuXi Biologics makes training a top priority. All our scientists and engineers go through rigorous instructional regimens before working on your critical programs.
Whether the issues you are facing relate to time limitations or technical issues, our team of industry experts is distinctively positioned to help meet your development challenges.
Quality & Performance
We provide quality control and operational systems that meet or exceed worldwide regulatory standards. WuXi Biologics is the first biologics manufacturing facility in China approved by the U.S. FDA and EMA to produce a commercial drug substance and drug product.(Learn more).
Partners worldwide including 13 of the 20 largest pharma
Successful client GMP audits